17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO on NASDAQ. Precision plans to start...
00:53 , Mar 2, 2019 |  BC Extra  |  Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ. Precision plans to start this...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
23:41 , Aug 3, 2018 |  BioCentury  |  Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
23:17 , May 24, 2018 |  BC Innovations  |  Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:21 , May 20, 2016 |  BC Extra  |  Financial News

Merus inches up after IPO

Bispecific antibody developer Merus B.V. (NASDAQ:MRUS) rose $0.04 to $10.04 in its first day of trading Thursday after it raised $55 million through the sale of 5.5 million shares at $10 in an IPO. Earlier...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

MCLA-117: Phase I/II started

Merus began an open-label, dose-escalation, international Phase I/II trial to evaluate MCLA-117 in up to 50 patients. The trial will enroll patients with relapsed or refractory AML and those aged >65 years with newly diagnosed...